Autolus Therapeutics plc (NASDAQ:AUTL) Expected to Announce Earnings of -$0.51 Per Share

Wall Street analysts expect Autolus Therapeutics plc (NASDAQ:AUTLGet Rating) to report earnings per share (EPS) of ($0.51) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Autolus Therapeutics’ earnings. The lowest EPS estimate is ($0.61) and the highest is ($0.45). Autolus Therapeutics reported earnings of ($0.53) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 3.8%. The business is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Autolus Therapeutics will report full-year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.28) to ($1.73). For the next fiscal year, analysts expect that the business will post earnings of ($1.98) per share, with EPS estimates ranging from ($2.38) to ($1.60). Zacks’ EPS averages are an average based on a survey of analysts that cover Autolus Therapeutics.

Autolus Therapeutics (NASDAQ:AUTLGet Rating) last released its quarterly earnings data on Thursday, March 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). Autolus Therapeutics had a negative net margin of 6,098.54% and a negative return on equity of 49.80%. During the same period in the prior year, the business earned ($0.82) EPS.

AUTL has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Autolus Therapeutics in a research note on Monday, December 20th. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a research note on Thursday, March 10th. Finally, Zacks Investment Research lowered Autolus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 21st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Autolus Therapeutics presently has an average rating of “Buy” and a consensus price target of $13.60.

A number of institutional investors have recently bought and sold shares of the stock. Syncona Portfolio Ltd purchased a new position in Autolus Therapeutics during the fourth quarter worth about $38,130,000. Frazier Management LLC grew its position in Autolus Therapeutics by 6.1% during the fourth quarter. Frazier Management LLC now owns 3,746,857 shares of the company’s stock worth $19,446,000 after buying an additional 216,200 shares in the last quarter. Pendal Group Ltd grew its position in Autolus Therapeutics by 2.6% during the fourth quarter. Pendal Group Ltd now owns 1,444,802 shares of the company’s stock worth $7,499,000 after buying an additional 36,485 shares in the last quarter. Woodline Partners LP purchased a new position in Autolus Therapeutics during the fourth quarter worth about $4,868,000. Finally, LGT Capital Partners LTD. purchased a new position in Autolus Therapeutics during the first quarter worth about $2,085,000. Institutional investors and hedge funds own 68.28% of the company’s stock.

NASDAQ:AUTL opened at $4.04 on Thursday. Autolus Therapeutics has a 52-week low of $3.42 and a 52-week high of $8.23. The firm has a market cap of $367.28 million, a price-to-earnings ratio of -2.04 and a beta of 1.54. The business’s fifty day moving average is $4.17 and its 200 day moving average is $5.06.

Autolus Therapeutics Company Profile (Get Rating)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

Further Reading

Get a free copy of the Zacks research report on Autolus Therapeutics (AUTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.